Literature DB >> 19357707

Reliability and convergent validity of two outcome instruments for pemphigus.

Misha Rosenbach1, Dedee F Murrell, Jean-Claude Bystryn, Sam Dulay, Sarah Dick, Steve Fakharzadeh, Russell Hall, Neil J Korman, Julie Lin, Joyce Okawa, Amit G Pandya, Aimee S Payne, Mathew Rose, David Rubenstein, David Woodley, Carmela Vittorio, Benjamin B Werth, Erik A Williams, Lynne Taylor, Andrea B Troxel, Victoria P Werth.   

Abstract

A major obstacle in performing multicenter controlled trials for pemphigus is the lack of a validated disease activity scoring system. Here, we assess the reliability and convergent validity of the PDAI (pemphigus disease area index). A group of 10 dermatologists scored 15 patients with pemphigus to estimate the inter- and intra-rater reliability of the PDAI and the recently described ABSIS (autoimmune bullous skin disorder intensity score) instrument. To assess convergent validity, these tools were also correlated with the Physician's Global Assessment (PGA). Reliability studies demonstrated an intra-class correlation coefficient (ICC) for inter-rater reliability of 0.76 (95% confirdence interval (CI)=0.61-0.91) for the PDAI and 0.77 (0.63-0.91) for the ABSIS. The tools differed most in reliability of assessing skin activity, with an ICC of 0.39 (0.17-0.60) for the ABSIS and 0.86 (0.76-0.95) for the PDAI. Intra-rater test-retest reliability demonstrated an ICC of 0.98 (0.96-1.0) for the PDAI and 0.80 (0.65-0.96) for the ABSIS. The PDAI also correlated more closely with the PGA. We conclude that the PDAI is more reproducible and correlates better with physician impression of extent. Subset analysis suggests that for this population of mild-to-moderate disease activity, the PDAI captures more variability in cutaneous disease than the ABSIS.

Entities:  

Mesh:

Year:  2009        PMID: 19357707      PMCID: PMC3010359          DOI: 10.1038/jid.2009.72

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  11 in total

1.  Measurement of body surface area involvement in atopic eczema: an impossible task?

Authors:  C R Charman; A J Venn; H C Williams
Journal:  Br J Dermatol       Date:  1999-01       Impact factor: 9.302

2.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.

Authors:  Dedee F Murrell; Sarah Dick; A R Ahmed; Masayuki Amagai; Maria A Barnadas; Luca Borradori; Jean-Claude Bystryn; Giuseppe Cianchini; Luis Diaz; David Fivenson; Russell Hall; Karen E Harman; Takashi Hashimoto; Michael Hertl; Nico Hunzelmann; Pilar Iranzo; Pascal Joly; Marcel F Jonkman; Yasuo Kitajima; Neil J Korman; Linda K Martin; Daniel Mimouni; Amit G Pandya; Aimee S Payne; David Rubenstein; Hiroshi Shimizu; Animesh A Sinha; David Sirois; Detlef Zillikens; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2008-03-14       Impact factor: 11.527

Review 3.  Outcome measures of disease severity in atopic eczema.

Authors:  C Charman; H Williams
Journal:  Arch Dermatol       Date:  2000-06

4.  Assessment of area of involvement in skin disease: a study using schematic figure outlines.

Authors:  S Tiling-Grosse; J Rees
Journal:  Br J Dermatol       Date:  1993-01       Impact factor: 9.302

5.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

Review 6.  Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus.

Authors:  Martin Pfütze; Andrea Niedermeier; Michael Hertl; Rüdiger Eming
Journal:  Eur J Dermatol       Date:  2007-02-27       Impact factor: 3.328

7.  Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life.

Authors:  Jennifer L Hundley; Christie L Carroll; Wei Lang; Beverly Snively; Gil Yosipovitch; Steven R Feldman; Joseph L Jorizzo
Journal:  J Am Acad Dermatol       Date:  2005-12-02       Impact factor: 11.527

8.  Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.

Authors:  Richard G Langley; Charles N Ellis
Journal:  J Am Acad Dermatol       Date:  2004-10       Impact factor: 11.527

9.  Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.

Authors:  Peter Heald; Marilyn Mehlmauer; Ann G Martin; Constance A Crowley; Richard C Yocum; Steven D Reich
Journal:  J Am Acad Dermatol       Date:  2003-11       Impact factor: 11.527

10.  A review of two controlled multicenter trials comparing 0.05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatoses.

Authors:  C A Guzzo; J S Weiss; H S Mogavero; C N Ellis; N Zaias; N J Lowe; F A Kerdel; J J Milbauer; J D Bernhard; C Whitmore
Journal:  J Am Acad Dermatol       Date:  1991-12       Impact factor: 11.527

View more
  40 in total

1.  Rituximab for autoimmune blistering diseases: recent studies, new insights.

Authors:  L Lunardon; A S Payne
Journal:  G Ital Dermatol Venereol       Date:  2012-06       Impact factor: 2.011

Review 2.  Pemphigus.

Authors:  Michael Kasperkiewicz; Christoph T Ellebrecht; Hayato Takahashi; Jun Yamagami; Detlef Zillikens; Aimee S Payne; Masayuki Amagai
Journal:  Nat Rev Dis Primers       Date:  2017-05-11       Impact factor: 52.329

3.  A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone.

Authors:  R P Hall; J Fairley; D Woodley; V P Werth; D Hannah; R D Streilein; J McKillip; J Okawa; M Rose; L L Keyes-Elstein; A Pinckney; A Overington; J Wedgwood; L Ding; B Welch
Journal:  Br J Dermatol       Date:  2015-02-05       Impact factor: 9.302

4.  Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.

Authors:  Dedee F Murrell; Benjamin S Daniel; Pascal Joly; Luca Borradori; Masayuki Amagai; Takashi Hashimoto; Frédéric Caux; Branka Marinovic; Animesh A Sinha; Michael Hertl; Philippe Bernard; David Sirois; Giuseppe Cianchini; Janet A Fairley; Marcel F Jonkman; Amit G Pandya; David Rubenstein; Detlef Zillikens; Aimee S Payne; David Woodley; Giovanna Zambruno; Valeria Aoki; Carlo Pincelli; Luis Diaz; Russell P Hall; Michael Meurer; Jose M Mascaro; Enno Schmidt; Hiroshi Shimizu; John Zone; Robert Swerlick; Daniel Mimouni; Donna Culton; Jasna Lipozencic; Benjamin Bince; Sergei A Grando; Jean-Claude Bystryn; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2011-11-05       Impact factor: 11.527

5.  The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists.

Authors:  J Tiao; R Feng; S Bird; J K Choi; J Dunham; M George; T C Gonzalez-Rivera; J L Kaufman; N Khan; J J Luo; R Micheletti; A S Payne; R Price; C Quinn; A I Rubin; A G Sreih; P Thomas; J Okawa; V P Werth
Journal:  Br J Dermatol       Date:  2016-12-22       Impact factor: 9.302

6.  Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease.

Authors:  Claire L Langrish; J Michael Bradshaw; Michelle R Francesco; Timothy D Owens; Yan Xing; Jin Shu; Jacob LaStant; Angelina Bisconte; Catherine Outerbridge; Stephen D White; Ronald J Hill; Ken A Brameld; David M Goldstein; Philip A Nunn
Journal:  J Immunol       Date:  2021-03-05       Impact factor: 5.422

Review 7.  Quality of life in patients with bullous dermatoses.

Authors:  Deshan F Sebaratnam; James R McMillan; Victoria P Werth; Dédée F Murrell
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 8.  Severity score indexes for blistering diseases.

Authors:  Benjamin S Daniel; Michael Hertl; Victoria P Werth; Rüdiger Eming; Dédée F Murrell
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

9.  Inter-rater reliability of cutaneous sarcoidosis assessment tools via remote photographic assessment.

Authors:  Sara A Berg; Howa Yeung; Joseph C English; Emily L Keimig; Ellen J Kim; Robert G Micheletti; Karolyn A Wanat; Marc A Judson; Robert P Baughman; Misha Rosenbach
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

10.  Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis.

Authors:  Misha Rosenbach; Howa Yeung; Emily Y Chu; Ellen J Kim; Aimee S Payne; Junko Takeshita; Carmela C Vittorio; Karolyn A Wanat; Victoria P Werth; Joel M Gelfand
Journal:  JAMA Dermatol       Date:  2013-05       Impact factor: 10.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.